Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 17/20 | 0.40 |
| ▸ | MCHR2 | Q969V1 | 4/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17678319 | 0.91 | EGFR (0.41) | IRAK4MCHR1MCHR2P2RX7 | |
| SCHEMBL17678140 | 0.91 | IRAK4 (0.47) | IRAK4MCHR1MCHR2P2RX7 | |
| SCHEMBL145462 | 0.85 | HDAC3 (0.44) | IRAK4MCHR1MCHR2 | |
| SCHEMBL17678143 | 0.84 | IRAK4 (0.49) | IRAK4MCHR1MCHR2 | |
| SCHEMBL17673663 | 0.83 | IRAK4 (0.47) | IRAK4MCHR1P2RX7KCNH2 | |
| SCHEMBL17678118 | 0.83 | IRAK4 (0.46) | IRAK4MCHR1P2RX7 | |
| SCHEMBL17678018 | 0.82 | IRAK4 (0.45) | IRAK4MCHR1P2RX7KCNH2 | |
| SCHEMBL15328953 | 0.81 | IRAK4 (0.45) | IRAK4 | |
| SCHEMBL2424027 | 0.80 | IRAK4 (0.47) | IRAK4 | |
| SCHEMBL23546459 | 0.79 | IRAK4 (0.43) | IRAK4MCHR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
| WO-2016057834-A9 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016057834-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | IRAK4 3515/4885MCHR1 3488/4885MCHR2 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.